Creative Financial Designs’s CRISPR Therapeutics CRSP Stock Holding History

Creative Financial Designs’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12	Closed	-$488	–	1408
2022 Q4	$488	Hold	12	–	–	﹤0.01%	1241
2022 Q3	$1K	Hold	12	–	–	﹤0.01%	1214
2022 Q2	$1K	Hold	12	–	–	﹤0.01%	1175
2022 Q1	$1K	Buy	12 +5	+71%	+$314	﹤0.01%	1197
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	1158
2021 Q3	$1K	Hold	7	–	–	﹤0.01%	1350
2021 Q2	$1K	Buy	7 +2	+40%	+$243	﹤0.01%	1370
2021 Q1	$1K	Buy	+5	New	+$755	﹤0.01%	1254

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Creative Financial Designs's CRSP Position: Q1 2023 in Review

Creative Financial Designs sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 12 shares — an estimated $488 sold.

Creative Financial Designs first reported a position in CRSP in Q1 2021 and held it in 8 quarters. The position peaked at $1K in Q3 2022. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Creative Financial Designs reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
Creative Financial Designs sold 12 CRISPR Therapeutics shares in Q1 2023, an estimated $488.
Creative Financial Designs first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 8 quarters.
Creative Financial Designs's CRISPR Therapeutics position peaked at $1K in Q3 2022.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Creative Financial Designs's 13F filing for Q1 2023, filed 25 Apr 2023.